It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- Based in California, Ardelyx is a clinical stage biotech focused on drugs to better manage complications related to kidney and cardiorenal diseases
- Click here for the latest corporate presentation
- Ardelyx has several Phase 3 studies and partners in; Japan, China and Canada
- Japan: Kyowa Kirin, $30 million upfront payment, development and commercialization milestones worth up to $130 million, and high-teen royalties
- China: Fuson Pharma, upfront payment of $12 million, additional milestones of up to $113 million, and tiered royalty payments from the mid-teens to 20%
- Canada: Knight Pharma, up to $25 million CAD
- Click here for an overview of Ardelyx pipeline